DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

When Anthony Cannella was first diagnosed with mantle cell lymphoma, his youngest child was in kindergarten. He was told that ...

Nkure Therapeutics and Crispr Therapeutics partner to develop off-the-shelf CAR T therapy for oncology in India.

Apr. 29, 2025 — A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete ...

NKure Therapeutics & CRISPR Therapeutics partner to advance CTX112 for cancer treatment in India: Our Bureau, Bengaluru Wednesday, May 7, 2025, 13:45 Hrs [IST] NKure Therapeutics, ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...

In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support ...

The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in EU to treat adult patients with previously untreated mantle cell lymphoma: Cambridge, UK Wednesday, May 7, 2025, 09:0 ...

Phase-I trial of HSPCAR30 therapy shows 100% response and 50% remission in CD30+ lymphoma patients with no major side effects ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

Roughly 200,000 people are diagnosed with a blood cancer on a yearly basis. Blood cancer will claim the lives of 55,000 ...